{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:03:39Z","timestamp":1790168619479,"version":"4.1.0"},"reference-count":29,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"DOI":"10.2340\/1651-226x.2026.46486","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:19:22Z","timestamp":1790165962000},"page":"776-780","source":"Crossref","is-referenced-by-count":0,"title":["Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2347-3591","authenticated-orcid":false,"given":"Karolina F.","family":"Larsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Forsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-6295","authenticated-orcid":false,"given":"Henrik","family":"Fagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9170-425X","authenticated-orcid":false,"given":"Maja","family":"Drakenberg Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-8180","authenticated-orcid":false,"given":"Matilda","family":"Liljedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-0393","authenticated-orcid":false,"given":"Christoffer","family":"Vannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"169170","doi-asserted-by":"crossref","unstructured":"Liu A, Peng P, Zhu Y, Fei Q, Liu W, Zhang S. Targeted therapies for each subtype of breast cancer. MedComm (2020). 2026;7:e70733.","DOI":"10.1002\/mco2.70733"},{"key":"169171","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","DOI":"10.1056\/NEJMoa1813904"},{"key":"169172","doi-asserted-by":"crossref","unstructured":"Drakenberg Danese MB, Vannas CP, Fagman HA, Karlsson PO, Larsson KF. PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set. Acta Oncol. 2026;65:401\u20135.","DOI":"10.2340\/1651-226X.2026.45589"},{"key":"169173","doi-asserted-by":"crossref","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"169174","doi-asserted-by":"crossref","unstructured":"Kornek G, Selzer E. Targeted therapies in solid tumours: pinpointing the tumour\u2019s Achilles heel. Curr Pharm Des. 2009;15(2):207\u201342.","DOI":"10.2174\/138161209787002906"},{"key":"169175","doi-asserted-by":"crossref","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473\u201380.","DOI":"10.1038\/nrc2394"},{"key":"169176","doi-asserted-by":"crossref","unstructured":"Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609\u201318.","DOI":"10.1056\/NEJM199811263392207"},{"key":"169177","doi-asserted-by":"crossref","unstructured":"Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes \u2013 an observational cohort study in Sweden. BMC Cancer. 2022;22(1):1006.","DOI":"10.1186\/s12885-022-10098-1"},{"key":"169178","doi-asserted-by":"crossref","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10(1):104103.","DOI":"10.1016\/j.esmoop.2024.104103"},{"key":"169179","doi-asserted-by":"crossref","unstructured":"Rani A, Stebbing J, Giamas G, Murphy J. Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 2019;10:245.","DOI":"10.3389\/fendo.2019.00245"},{"key":"169180","doi-asserted-by":"crossref","unstructured":"Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690.","DOI":"10.3389\/fphar.2021.628690"},{"key":"169181","unstructured":"Cardoso F. 7th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC7). Ann Oncol. 2024;35(3):213\u201332."},{"key":"169182","doi-asserted-by":"crossref","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u201338.","DOI":"10.1016\/S1470-2045(24)00673-9"},{"key":"169183","doi-asserted-by":"crossref","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.","DOI":"10.1016\/j.breast.2024.103756"},{"key":"169184","unstructured":"BioInvent International AB. BI-1808 as a single agent and with Pembrolizumab (KEYTRUDA\u00ae) in Treatment of Advanced Malignancies (KEYNOTE-D20). Bethesda (MD): U.S. National Library of Medicine; 2021. ClinicalTrialsgov."},{"key":"169185","doi-asserted-by":"crossref","unstructured":"Ny L, Fagman H, Botling J, Mantovaara L, Asplund P, Karlsson H, et al. Feasibility and outcome of genomics-guided treatment selection in advanced cancer \u2013 the MEGALiT explorative clinical trial. Acta Oncol. 2025;64:742\u201350.","DOI":"10.2340\/1651-226X.2025.43366"},{"key":"169186","unstructured":"Food US, Drug A. FoundationOne CDx (F1CDx) \u2013 P170019\/S048. Silver Spring (MD): U.S. Food and Drug Administration; 2023. FDA Recently Approved Devices."},{"key":"169187","doi-asserted-by":"crossref","unstructured":"Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29(6):1056\u201367.","DOI":"10.1158\/1078-0432.CCR-22-2115"},{"key":"169188","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, Adamo B, Vidal M, Gonz\u00e1lez-Farr\u00e9 B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45.","DOI":"10.1186\/s13058-020-01284-9"},{"key":"169189","doi-asserted-by":"crossref","unstructured":"Tharin Z, Richard C, Derang\u00e8re V, Ilie A, Arnould L, Ghiringhelli F, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. Sci Rep. 2023;13(1):4467.","DOI":"10.1038\/s41598-023-31593-w"},{"key":"169190","doi-asserted-by":"crossref","unstructured":"Schagerholm C, Robertson S, Toosi H, Sifakis EG, Hartman J. PIK3CA mutations in endocrine-resistant breast cancer. Sci Rep. 2024;14(1):12542.","DOI":"10.1038\/s41598-024-62664-1"},{"key":"169191","doi-asserted-by":"crossref","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427\u201338.e6.","DOI":"10.1016\/j.ccell.2018.08.008"},{"key":"169192","doi-asserted-by":"crossref","unstructured":"Jenkins ML, Ranga-Prasad H, Parson MAH, Harris NJ, Rathinaswamy MK, Burke JE. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. Nat Commun. 2023;14(1):181.","DOI":"10.1038\/s41467-023-35789-6"},{"key":"169193","doi-asserted-by":"crossref","unstructured":"Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A. 2007;104(19):7809\u201314.","DOI":"10.1073\/pnas.0700373104"},{"key":"169194","doi-asserted-by":"crossref","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.","DOI":"10.1126\/science.1096502"},{"key":"169195","doi-asserted-by":"crossref","unstructured":"Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110\u03b1 (PIK3CA). Proc Natl Acad Sci U S A. 2012;109(38):15259\u201364.","DOI":"10.1073\/pnas.1205508109"},{"key":"169196","unstructured":"Institute NC. [cited 2025 Oct 14]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/targeted-therapy2025"},{"key":"169197","doi-asserted-by":"crossref","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370.","DOI":"10.1056\/NEJMoa2214131"},{"key":"169198","doi-asserted-by":"crossref","unstructured":"Nilbert M. The promises of precision medicine \u2013 voices from the Nordics. Acta Oncol. 2025;64:775\u20137.","DOI":"10.2340\/1651-226X.2025.43987"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/46486\/55597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/46486\/55597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:19:36Z","timestamp":1790165976000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/46486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.46486","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}